Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
TENX 
Tenax Therapeutics Inc (TENX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/29/2025: TENX (3-star) is a STRONG-BUY. BUY since 110 days. Simulated Profits (99.35%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22.9
1 Year Target Price $22.9
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 105.86% | Avg. Invested days 55 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 76.05M USD | Price to earnings Ratio - | 1Y Target Price 22.9 |
Price to earnings Ratio - | 1Y Target Price 22.9 | ||
Volume (30-day avg) 4 | Beta 1.55 | 52 Weeks Range 4.63 - 14.22 | Updated Date 12/30/2025 |
52 Weeks Range 4.63 - 14.22 | Updated Date 12/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.74 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -29.14% | Return on Equity (TTM) -44.8% |
Valuation
Trailing PE - | Forward PE 0.3 | Enterprise Value 66941530 | Price to Sales(TTM) - |
Enterprise Value 66941530 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.14 | Shares Outstanding 6243575 | Shares Floating 6165881 |
Shares Outstanding 6243575 | Shares Floating 6165881 | ||
Percent Insiders 0.31 | Percent Institutions 102.22 |
About Tenax Therapeutics Inc
Exchange NASDAQ | Headquaters Chapel Hill, NC, United States | ||
IPO Launch date 1997-01-02 | CEO, President & Director Mr. Christopher T. Giordano | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.tenaxthera.com |
Full time employees 4 | Website https://www.tenaxthera.com | ||
Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.